Global innovative biopharma
Pfizer Inc.
Pfizer develops prescription medicines and vaccines and sells them through major wholesalers and directly to healthcare providers and governments. It pays contract manufacturers and collaboration partners, while using acquisitions to expand its obesity, cardiometabolic and oncology pipelines.
PFE Updated Sep 12, 2026 3 AI consumers· 2 recurring
Per the valuechain.wiki graph, Pfizer Inc. is directly linked to 5 companies (2 supply, 3 revenue relationships) and reaches 10 companies within two hops; the links are backed by 5 dated sources, 2 of them primary filings (as of 2026-09-12).
Financials & Segments
- Total revenue · FY2025 total revenue USD 62,579,000,000 (PFIZER INC 2025 Form 10-K, 2026-02-26)
- Segments · Biopharma · Other
Revenue from
- McKesson Corporation High confidence· Revenue share 25 percent · FY2025 · Share of Pfizer FY2025 total revenue generated from McKesson
McKesson is Pfizer's largest U.S. wholesaler customer. Its share of Pfizer's total revenue increased in FY2025 from the prior year. - Cencora High confidence· Revenue share 16 percent · FY2025 · Share of Pfizer FY2025 total revenue generated from Cencora
Cencora is Pfizer's second-largest U.S. wholesaler customer and accounted for a material share of FY2025 total revenue. - Cardinal Health High confidence· Revenue share 13 percent · FY2025 · Share of Pfizer FY2025 total revenue generated from Cardinal Health
Cardinal Health is Pfizer's third-largest U.S. wholesaler customer and represented a double-digit share of FY2025 total revenue.
Pays to
- BioNTech SE High confidence· Amount $911M · 2025-12-31 · Amount payable to BioNTech for the Comirnaty gross profit split
Pfizer shares Comirnaty gross profit with BioNTech. Pfizer disclosed the amount payable to BioNTech at the end of 2025. - Samsung Biologics Medium confidence· Contract value ₩922.8B · 2023-06-30/2029-12-31 · Value of the Pfizer contract manufacturing supply agreement disclosed in July 2023
Samsung Biologics provides contract manufacturing services for Pfizer. A securities research report details the value and term of the agreement disclosed in July 2023.Confirms KO Hyundai Motor Securities Published Jan 12, 2024: Samsung Biologics: Watch the Pace of New OrdersConfirms KO Samsung Biologics Published Jul 4, 2023: Samsung Biologics Wins KRW 1.2 Trillion of Pfizer Manufacturing Contracts - Agilent Technologies, Inc. Medium confidence
Pfizer used a dedicated Agilent CrossLab team at a 24/7 production site for instrument maintenance, qualification, compliance, and asset monitoring, while the contract value and revenue attributable to Agilent were not disclosed.
Investments
- Metsera, Inc. High confidence· Amount $8B · 2025-11-13 · Total fair value of consideration transferred for the Metsera acquisition
Pfizer acquired obesity and cardiometabolic drug developer Metsera in November 2025. The consideration included contingent value rights and employee stock awards related to pre-acquisition service.
Value-chain ripple (2 tiers)
Following node-to-node links up to 2 tiers; each firm is shown once, at its nearest tier.
| Company | Chain | '21 | '22 | '23 | '24 | '25 | YTD |
|---|---|---|---|---|---|---|---|
| CVS Health | lead2 | +54.9 | -7.6 | -12.5 | -40.8 | +84.3 | +24.7 |
| Walmart Inc | lead2 | +2 | -0.5 | +12.9 | +74 | +24.5 | -3.2 |
| Cardinal Health, Inc. | lead1 | -0.4 | +54.1 | +34.1 | +19 | +76.3 | +21.1 |
| McKesson Corporation | lead1 | +44.2 | +51.8 | +24.1 | +23.7 | +44.5 | +11 |
| Cencora, Inc. | lead1 | +44.1 | +26.3 | +25.3 | +10.4 | +51.5 | -1.4 |
| Pfizer Inc. | node | +66.7 | -10.4 | -41.3 | -2.2 | +0.6 | +20.2 |
| Agilent Technologies, Inc. | benef1 | +35.5 | -5.5 | -6.4 | -2.7 | +1.9 | +11.5 |
| Samsung Biologics | benef1 | -6.8 | +8.6 | +5.8 | +28.7 | +5 | -17.1 |
| Samsung E&A | benef2 | +74.5 | +20 | -13.7 | -15.9 | +76.7 | +48.9 |
| Amazon | benef2 | +2.4 | -49.6 | +80.9 | +44.4 | +5.2 | +12 |
| Danaher Corporation | benef2 | +48.6 | -19 | -1.2 | -0.3 | +0.4 | -8.9 |
YTD as of 2026-09-04 · source: Yahoo Finance
Pfizer Inc. operates across Global innovative biopharma. It is +20.2% in 2026. The stock (+20.2%) and its supply side (avg -17.1%) are moving in step. It pays contract manufacturers and collaboration partners, while using acquisitions to expand its obesity, cardiometabolic and oncology pipelines.
Analysis generated from returns as of 2026-09-04